Publication Details
Abstract
Hyperprolactinemia syndrome, predominantly caused by prolactin-secreting pituitary adenomas (prolactinomas), is characterized by elevated serum prolactin levels leading to reproductive dysfunction, galactorrhea, infertility, hypogonadism, and metabolic disturbances. Management strategies include pharmacological therapy with dopamine agonists, surgical resection, and, in selected cases, radiotherapy. Accurate assessment of treatment outcomes is crucial to optimize hormone normalization, tumor size reduction, symptom resolution, and long-term patient quality of life. This review analyzes current therapeutic approaches, evaluates efficacy, complications, and recurrence rates, and highlights strategies for individualized management. Advances in imaging, endocrine monitoring, and minimally invasive surgical techniques have improved prognostic accuracy and guided tailored interventions. The article underscores evidence-based protocols for achieving optimal clinical, biochemical, and radiological outcomes in patients with prolactinomas. Hyperprolactinemia syndrome, most frequently caused by prolactin-secreting pituitary adenomas, is a significant endocrine disorder characterized by excessive serum prolactin levels that disrupt reproductive function, induce galactorrhea, and lead to hypogonadism, infertility, and metabolic abnormalities. The accurate evaluation of therapeutic outcomes is essential to ensure normalization of prolactin, tumor shrinkage, alleviation of clinical symptoms, and long-term quality-of-life improvement. This review analyzes the effectiveness, safety, and long-term results of pharmacological and surgical interventions for prolactinomas, emphasizing individualized treatment strategies. Modern imaging, minimally invasive surgical techniques, and refined endocrine monitoring have enhanced the precision of diagnosis, guided personalized interventions, and improved prognostic accuracy. The article highlights evidence-based protocols for achieving optimal clinical, biochemical, and radiological results in patients with prolactin-secreting pituitary adenomas.